Dr Lisa Philp
Faculty of Health,
School of Biomedical Sciences
Personal details
Positions
- Research Fellow
Faculty of Health,
School of Biomedical Sciences
Keywords
adipokines, preclinical therapeutic development, animal models of human disease, endocrinology, obesity, metabolism, prostate cancer, acute respiratory distress syndrome
Research field
Pharmacology and pharmaceutical sciences, Medical physiology
Field of Research code, Australian and New Zealand Standard Research Classification (ANZSRC), 2020
Qualifications
- PhD (University of Adelaide)
Professional memberships and associations
2019-current Chair of the Translational Research Institute Mentoring Committee
2019- current Translational Research Institute Education and Training Committee
2019- current Translational Research Institute Student Retreat Committee
2018-current Translational Research Institute Biological Resource Facility User Group Committee, QUT representative
2018-current Translational Research Institute Postdoc Network
2018-current Movember Revolutionary Team Award “Adaptive Response to Targeting the Androgen Axis –A Strategic Offensive on Resistance” Executive Committee
Current Professional Memberships:
2019-current Society for Endocrinology (international)
2018-current American Association for Cancer Research (international)
2018-current Translational Research Institute Mentoring Network
2018-current Translational Research Institute Postdoc Network
2017-current Queensland University of Technology Women in STEMM program
2014- current The Endocrine Society (international)
2004- current Golden Key International Honor Society (international)
Experience
Since joining the APCRC-Q in 2014, Dr Philp's work investigating the key role of adipokines in prostate cancer progression contributed to that of a large multi-disciplinary team of researchers at the APCRC-Q investigating the Adaptive Response to Targeting the Androgen Axis –A Strategic Offensive on Resistance in Prostate Cancer, that saw $6.25M funding awarded between 2014-2019 through a Movember Revolutionary Team Award. Her work demonstrating the importance of the adiponectin axis in prostate cancer progression, and the potent efficacy of targeting adiponectin signalling to halt tumour progression has seen her team most recently receive funding through a US Department of Defense Prostate Cancer Research Program - Idea Award of $US853896 (2020-2023). She was also recently awarded a 2020 Advance Queensland Industry Research Fellowship (AU$150,000) for her project "Preventing the respiratory failure causing COVID-19 mortality, potent new drugs targeting hyperinflammation". Through this work, Dr Philp has strong industry linkages with two independent biotech/pharmaceutical companies based in the US, and collaborations with clinicians scientists and hospital partners.
Current projects are focused on the preclinical development of drugs, targeting adipokine signalling, in a quest to prevent disease, including prostate cancer progression to treatment resistance and acute respiratory distress syndrome.
These projects include:
1. Restoring the adiponectin axis as a novel prostate cancer therapy.
2. Targeting the dysregulation of leptin to combat treatment resistance in advanced prostate cancer.
3. Exploring the ying-yang of adipokines in human disease.
4. Preventing the respiratory failure causing COVID-19 mortality, potent new drugs targeting hyperinflammation.
Publications
QUT ePrints
For more publications by Lisa, explore their research in QUT ePrints (our digital repository).
Selected research projects
- Title
- Adaptive Response to Targeting the Androgen Axis: A Strategic Offensive on Resistance (Stage 2)
- Primary fund type
- CAT 1 - Australian Competitive Grant
- Project ID
- Start year
- 2017
- Keywords
Projects listed above are funded by Australian Competitive Grants. Projects funded from other sources are not listed due to confidentiality agreements.